American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer

American Journal of Clinical Pathology

Volumn 137, Issue 4, 2012, Pages 516-542

  Saslow, Debbie ^a   Solomon, Diane ^b   Lawson, Herschel W ^c   Killackey, Maureen ^d   Kulasingam, Shalini L ^e   Cain, Joanna ^f   Garcia, Francisco A R ^g   Moriarty, Ann T ^h   Waxman, Alan G ⁱ   Wilbur, David C ^j   Wentzensen, Nicolas ^b   Downs, Levi S ^k   Spitzer, Mark ^l   Moscicki, Anna Barbara ^m   Franco, Eduardo L ⁿ   Stoler, Mark H ^o   Schiffman, Mark ^b   Castle, Philip E ^p   Myers, Evan R ^q  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h Ameripath Inc   (United States)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ MCGILL UNIVERSITY   (Canada)

^o UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^p American Society for Clinical Pathology   (United States)

^q DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLPOSCOPY; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYSTERECTOMY; NON PROFIT ORGANIZATION; PAPANICOLAOU TEST; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERUS CARCINOMA; VAGINA CANCER; VIRUS INFECTION; WART VIRUS; CYTODIAGNOSIS; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; STANDARD; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84860564294     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPTGD94EVRSJCG     Document Type: Article

References (158)

1. Saslow D, Runowicz CD, Solomon D, et al., American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362. (Pubitemid 35446606)
2. Wright TC Jr., Massad LS, Dunton CJ, et al., 2006 American Society for Colposcopy and Cervical Pathology-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201-222. (Pubitemid 47530909)
3. Gustafsson L, Ponten J, Bergstrom R, et al. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71:159-165. (Pubitemid 27252984)
4. Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8:755-763. (Pubitemid 27404646)
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(suppl 3):S3/11-25.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
7. American Cancer Society. Cancer Facts & Figures 2012 . Atlanta, GA: American Cancer Society; 2012.
8. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
9. de Sanjose S, Quint WG, Alemany L, et al., Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
10. Munoz N, Bosch FX, de Sanjose S, et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
11. Wright TC Jr., Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348:489-490. (Pubitemid 36159883)
12. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. (Pubitemid 47371147)
13. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data. 2005:1-55.
14. Plummer M, Schiffman M, Castle PE, et al., ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582- 1589.
15. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513-517.
16. Castle PE, Rodriguez AC, Burk RD, et al., Proyecto Epidemiologico Guanacaste Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009;339:b2569.
17. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478-1488.
18. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-434.
19. Castle PE, Fetterman B, Cox JT, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol. 2010;116:76-84.
20. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
21. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52. (Pubitemid 36124295)
22. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
23. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011;20:1398-1409.
24. Freeman H, Wingrove B. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities . Rockville, MD: National Cancer Institute; 2005.
25. Division of Cancer Prevention and Control, National Center for Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Cervical Cancer . Atlanta, GA: 2011. http://www.cdc.gov/cancer/cervical/. Accessed October 21, 2011.
26. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45:93-106. (Pubitemid 47348085)
27. Scarinci IC, Garcia FA, Kobetz E, et al. Cervical cancer prevention: new tools and old barriers. Cancer. 2010;116:2531-2542.
28. Castle PE, Stoler MH, Solomon D, et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127:805-815.
29. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18- 25.
30. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11:4717-4723. (Pubitemid 41557190)
31. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.
32. Sirovich BE, Woloshin S, Schwartz LM. Screening for cervical cancer: will women accept less? Am J Med. 2005;118:151-158. (Pubitemid 40202863)
33. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14:73-80.
34. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 109: Cervical cytology screening. Obstet Gynecol. 2009;114:1409-1420.
35. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167-177.
36. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302:1757-1764.
37. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101. (Pubitemid 44116919)
38. Mayrand MH, Duarte-Franco E, Rodrigues I, et al., Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588. (Pubitemid 47598400)
39. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597. (Pubitemid 47598401)
40. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-1772. (Pubitemid 350137476)
41. Ronco G, Giorgi-Rossi P, Carozzi F, et al., New Technologies for Cervical Cancer Screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.
42. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804.
43. Castle PE, Stoler MH, Wright TC Jr., et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12:880-890.
44. Stoler MH. HPV for cervical cancer screening: is the era of the molecular Pap smear upon us? J Histochem Cytochem. 2001;49:1197-1198. (Pubitemid 32800545)
45. Castle PE, Wheeler CM, Solomon D, et al., ALTS Group. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004;122:238-245. (Pubitemid 38971357)
46. Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol. 2005;124:716-721.
47. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516-520.
48. Stoler MH, Castle PE, Solomon D, et al., American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127:335-337. (Pubitemid 46806325)
49. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol. 2010;134:193-199.
50. Cubie HA, Moore C, Waller M, et al., National Cervical Screening Committee LBC/HPV Pilot Steering Group. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies. J Clin Virol. 2005;33:287-292. (Pubitemid 40982517)
51. Guyatt GH, Oxman AD, Kunz R, et al., GRADE Working Group. Going from evidence to recommendations. BMJ. 2008;336:1049-1051.
52. Guyatt GH, Oxman AD, Kunz R, et al., GRADE Working Group. Incorporating considerations of resources use into grading recommendations. BMJ. 2008;336:1170-1173. (Pubitemid 351809277)
53. Guyatt GH, Oxman AD, Kunz R, et al., GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995- 998.
54. Guyatt GH, Oxman AD, Vist GE, et al., GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926. (Pubitemid 351632017)
55. Jaeschke R, Guyatt GH, Dellinger P, et al., GRADE Working Group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
56. Schunemann HJ, Oxman AD, Brozek J, et al., GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-1110. (Pubitemid 351731739)
57. Kaplan JE, Benson C, Holmes KH, et al., Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
58. Castle PE, Carreon JD. Practice improvement in cervical screening and management: symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14:238-240; author reply 240.
59. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.
60. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28. (Pubitemid 46148088)
61. Markowitz LE, Dunne EF, Saraiya M, et al., Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56 (RR-2):1-24.
62. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, et al. Tradeoffs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med. 2008;168:1881-1889.
63. Kulasingam S, Havrilesky L, Ghebre R, et al. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force . Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ Pub. No. 11-05157-EF-1.
64. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer. 1996;73:1001-1005. (Pubitemid 26116757)
65. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89:88- 93.
66. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819. (Pubitemid 46333946)
67. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001;183:1554-1564. (Pubitemid 32466692)
68. Canfell K, Barnabas R, Patnick J, et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91:530-536. (Pubitemid 39093574)
69. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619-631. (Pubitemid 40459019)
70. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97:888-895. (Pubitemid 41417940)
71. Miller MG, Sung HY, Sawaya GF, et al. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol. 2003;101:29-37. (Pubitemid 36057085)
72. Gram IT, Macaluso M, Stalsberg H. Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening. Acta Obstet Gynecol Scand. 1998;77:228-232. (Pubitemid 28075396)
73. Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med. 2003;349:1501-1509. (Pubitemid 37255035)
74. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-672.
75. Australian Institute of Health and Welfare. Cervical Screening in Australia 2008-2009. Canberra, Australian Capital Territory, Australia: Australian Institute of Health and Welfare; 2011.
76. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14:2191-2199 (Pubitemid 41603267)
77. Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004;100:1035-1044. (Pubitemid 38232621)
78. Wright TC Jr., Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
79. Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010;170:977-985.
80. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(suppl 3):S3/78-89.
81. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505. (Pubitemid 32221899)
82. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672-682.
83. Sasieni P, Castle PE, Cuzick J. Further analysis of the ARTISTIC trial. Lancet Oncol. 2009;10:841-842.
84. Vijayaraghavan A, Efrusy MB, Mayrand MH, et al. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. Can J Public Health. 2010;101:220-225.
85. Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104:232-246. (Pubitemid 46054137)
86. Mitchell H, Medley G, Gordon I, et al. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer. 1995;71:894-897.
87. Zappa M, Visioli CB, Ciatto S, et al. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004;90:1784-1786. (Pubitemid 38725653)
88. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885-891.
89. Castellsague X, Diaz M, de Sanjose S, et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-315.
90. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
91. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer. 2010;126:684-691.
92. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079. (Pubitemid 41417924)
93. Wright TC Jr., Stoler MH, Sharma A, et al., ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV-16 and HPV- 18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136:578-586.
94. Chen HC, Schiffman M, Lin CY, et al., CBCSP-HPV Study Group. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103:1387-1396.
95. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101:475-487.
96. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927-935.
97. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 1999;80:1306-1311. (Pubitemid 29308597)
98. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876. (Pubitemid 37518501)
99. Thrall MJ, Russell DK, Facik MS, et al. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. Am J Clin Pathol. 2010;133:894-898.
100. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66:10630-10636. (Pubitemid 44799787)
101. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996;68:766-769. (Pubitemid 27062038)
102. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942-953. (Pubitemid 39273789)
103. Stoler MH, Wright TC Jr., Sharma A, et al., ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135:468-475.
104. Safaeian M, Solomon D, Wacholder S, et al. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol. 2007;109:1325-1331. (Pubitemid 46869871)
105. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97:1066-1071. (Pubitemid 41417923)
106. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600.
107. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500. (Pubitemid 351665417)
108. Carozzi F, Confortini M, Dalla Palma P, et al., New Technologies for Cervical Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9:937-945.
109. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;101:1612-1623.
110. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864-871.
111. Vesco K, Whitlock E, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 86. Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ Pub. No. 11-05156-EF-1.
112. Sorbye SW, Fismen S, Gutteberg T, et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One. 2010;5:e12724.
113. Copeland G, Datta SD, Spivak G, et al. Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985-2003. Cancer. 2008;113 (suppl 10):2946-2954.
114. Mandelblatt J, Gopaul I, Wistreich M. Gynecological care of elderly women: another look at Papanicolaou smear testing. JAMA. 1986;256:367-371. (Pubitemid 16093269)
115. Sawaya GF, Kerlikowske K, Lee NC, et al. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol. 2000;96:219- 223.
116. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675-683. (Pubitemid 40812631)
117. Melnikow J, McGahan C, Sawaya GF, et al. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst. 2009;101:721-728.
118. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118:2048-2055.
119. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102:315-324.
120. Wu X, Matanoski G, Chen VW, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer. 2008;113(suppl 10):2873-2882.
121. Pearce KF, Haefner HK, Sarwar SF, et al. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. N Engl J Med. 1996;335:1559-1562. (Pubitemid 26384750)
122. Piscitelli JT, Bastian LA, Wilkes A, et al. Cytologic screening after hysterectomy for benign disease. Am J Obstet Gynecol. 1995;173:424-430.
123. Videlefsky A, Grossl N, Denniston M, et al. Routine vaginal cuff smear testing in post-hysterectomy patients with benign uterine conditions: when is it indicated? J Am Board Fam Pract. 2000;13:233-238. (Pubitemid 33607681)
124. Fox J, Remington P, Layde P, et al. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am J Obstet Gynecol. 1999;180:1104-1109. (Pubitemid 29259001)
125. Wiener JJ, Sweetnam PM, Jones JM. Long term follow up of women after hysterectomy with a history of pre-invasive cancer of the cervix. Br J Obstet Gynaecol. 1992;99:907-910.
126. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR. Morb Mortal Wkly Rep. 2011;60:1117-1123.
127. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915- 1927.
128. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196:1438-1446.
129. Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-1868. (Pubitemid 46829356)
130. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926-935.
131. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325-339.
132. Paavonen J, Naud P, Salmeron J, et al., HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
133. Romanowski B, de Borba PC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975-1985.
134. Gauthier A, Martin-Escudero V, Moore L, et al. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. Eur J Public Health. 2008;18:674-680.
135. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399-5408. (Pubitemid 46977529)
136. Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer. 2010;102:933-939.
137. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443-8450.
138. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41. (Pubitemid 46057835)
139. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12:343-351.
140. Sigurdsson K, Sigvaldason H, Gudmundsdottir T, et al. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening. Acta Obstet Gynecol Scand. 2009;88:27-35.
141. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615. (Pubitemid 38584984)
142. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789. (Pubitemid 37432955)
143. Coupe VM, Berkhof J, Bulkmans NW, et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98:646-651. (Pubitemid 351214513)
144. Diaz M, de Sanjose S, Ortendahl J, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010;46:2973- 2985.
145. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007;4:165-175. (Pubitemid 47339645)
146. Kulasingam SL, Pagliusi S, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine. 2007;25:8110-8113. (Pubitemid 350046322)
147. Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care. 2009;25:161-170.
148. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV- 16,18 vaccination. J Natl Cancer Inst. 2008;100:308-320. (Pubitemid 351480523)
149. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(suppl 3):S3/171-177.
150. Franco EL, Mahmud SM, Tota J, et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009;40:478-485.
151. Coupe VM, van Ginkel J, de Melker HE, et al. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer. 2009;124:970-978.
152. New Mexico Human Papillomavirus (HPV) Pap Registry (NMHPVPR) and HOPE Clinic (House of Prevention Epidemiology). http://www.unm.edu/~nmhpvpr/. Accessed January 15, 2012.
153. Hariri S, Unger ER, Powell SE, et al., The HPV-IMPACT Working Group. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control. 2012;23:281-288.
154. Public Health Agency of Canada. Performance Monitoring for Cervical Cancer Screening Programs in Canada: Report From the Screening Performance Indicators Working Group, Cervical Cancer Prevention and Control Network. Ottawa, Ontario, Canada; 2009.
155. Belinson JL, Du H, Yang B, et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing [published online ahead of print May 31, 2011]. Int J Cancer.doi:.
156. Castle PE, Rausa A, Walls T, et al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med. 2011;52:452-455.
157. Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306:2495- 2499.
158. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88.